Proprietary Products Proven to Protect Pets
LIHUE KAUAI, HI, April 18 /CNW/ - CEAPRO Inc. ("CEAPRO") (TSX-V CZO)
today announced the U.S. launch of Ceapro Dermatology pet care products,
approved by and sold through veterinarians. Ceapro is capitalizing on its
animal health product successes elsewhere by entering the U.S. market - a
significant thrust as the American market constitutes over 70% of global
animal health sales.
Ceapro Dermatology products are unique in using 100% bioavailable oat
actives(TM). Unlike most other oat products, all our patented active
ingredients are fully soluble, providing immediate penetration of active
components. Importantly, Ceapro's patented processes and analytical procedures
produce standardized extracts, guaranteeing product consistency and proven
clinical performance, so offering over-the-counter reliability for pets. The
all natural shampoo, ear cleaner, and dermal complex are formulated to
naturally improve pet health and reduce the need for steroid treatments.
Ceapro's full range of veterinary therapeutics provides an integrated
approach to health in animals. The products, which help reduce the incidence
of skin and ear disease while minimizing the need for active treatment, are
available exclusively through veterinarians. Hence the timing and location of
the launch: to over 300 veterinary practitioners attending the North American
Veterinary Dermatology Forum in Hawaii from 18-22 April, 2007. The rollout is
supported by a dedicated website: www.ceaproderm.com.
To ensure veterinarians nationwide are fully informed of the technical
advances of Ceapro Dermatology's products, the Company will sell through
well-connected, experienced distributors with established access to
veterinarians throughout the U.S. This mirrors the successful marketing of
Ceapro's veterinary therapeutics throughout Europe, Asia, Asia-Pacific, and
Ceapro Dermatology products will also be available online through
www.ceaproderm.com, with a veterinary rebate incentive program.
About Ceapro Inc.
Ceapro Inc is a Canadian growth-stage biotechnology company. Ceapro's
core technology is the extraction of functional, active ingredients from
plants and other renewable resources. We add further value to our extracts by
manufacturing medical and therapeutic products, and by supporting the use of
our extracts in products for human and animal health. We have also introduced
health and wellness services employing our CeaProve(R) diagnostic technology.
Our most recent initiative is the creation of Ceapro BioEnergy Inc. (CBE), a
wholly-owned subsidiary to utilize Ceapro's proprietary technology for the
production of ethanol and value-added products. Ceapro shares trade on the
Canadian TSX Venture Exchange under the symbol CZO. To learn more about
Ceapro, visit our website at www.ceapro.com.
The TSX-Venture has neither approved nor disapproved of the information
contained herein and does not accept responsibility for the adequacy or
accuracy of this release.
This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the
forward-looking statements contained herein are reasonable, it can give no
assurance that the Company's expectations are correct. All forward-looking
statements are expressly qualified in their entirety by this cautionary
For further information:
For further information: Dr. Mark Redmond, President and CEO, Ceapro
Inc., Telephone (Edmonton): (780) 421-4555; Nicole Blanchard, B.Sc., B.Comm.,
Managing Partner, Sun International Communications, Telephone (Montreal):